search for




 

First experience of pancreaticoduodenectomy using Revo-i in a patient with insulinoma
Ann Hepatobiliary Pancreat Surg 2020 Feb;24(1):104-8
Published online February 29, 2020;  https://doi.org/10.14701/ahbps.2020.24.1.104
Copyright © 2020 Korean Association of Hepato-Biliary-Pancreatic Surgery.

Incheon Kang1,2, Ho Kyoung Hwang1,2, Woo Jung Lee1,2, and Chang Moo Kang1,2

1Division of Hepatobiliary and Pancreatic Surgery, Department of Surgery, Yonsei University College of Medicine, 2Pancreatobiliary Cancer Center, Yonsei Cancer Center, Severance Hospital, Seoul, Korea
Received July 11, 2019; Revised July 13, 2019; Accepted July 15, 2019.
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
 Abstract
Robotic surgery systems have been developed to overcome the limitations of laparoscopic surgery. Recently, Meere-company Inc. in Korea successfully manufactured a robotic surgical system called Revo-i. A 65-year old woman was referred for a pancreatic head tumor, detected as an incidental finding during a routine check-up. Contrast abdominopelvic CT revealed a pancreatic uncinate tumor measuring around 13 mm in diameter, with no other focal lesions. The patient underwent a robot-assisted pancreaticoduodenectomy (laparoscopic resection and robotic reconstruction) using Revo-i. The patient’s recovery was uneventful and discharged on postoperative day 7. Our case showed the technical feasibility of the Korean robotic surgical system Revo-i. Further experiences are mandatory to validate this finding.
Keywords : Robotic surgical system; Pancreaticoduodenectomy; Robot surgery

 

February 2020, 24 (1)